Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03170063 · ClinicalTrials.gov registry record
FoxBioNet Pilot Project: SAVE (Synuclein Assay Validation Effort)
A clinical trial of Parkinson Disease, sponsored by Michael J. Fox Foundation for Parkinson's Research.
- Completed
- Registry status
- 54
- Enrollment target
- 5
- Study locations
NCT03170063: Completed study of Parkinson Disease, sponsored by Michael J. Fox Foundation for Parkinson's Research.
NCT03170063 is a study of Parkinson Disease that has completed, run by Michael J. Fox Foundation for Parkinson's Research. The registered enrollment target is 54 participants, below the 5,326-participant average among 297 other Parkinson Disease trials with a reported enrollment target (99% lower). The trial reports 5 study locations across 5 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03170063, a study of Parkinson Disease, has completed, sponsored by Michael J. Fox Foundation for Parkinson's Research.
- COMPLETED
- Registry status
- 54 participants
- Enrollment target
- 5
- Study locations
Study Summary
The overall objective of this study is to compare the performance of available oligomeric and phosphorylated a-synuclein assay in cerebrospinal fluid and blood.
Primary Outcome
CSF, serum, and plasma will be analyzed using oligomeric and pS129 assays. The outcome will be expressed as a concentration of modified (pS129 or oligomeric) synuclein or as a ratio of specific species to total synuclein levels.
Conditions Studied
Interventions
- PROCEDURE Procedure/Surgery: Biofluid samplings
Study Locations (5)
Illinois
- Rush University Medical Center - Chicago
Massachusetts
- Beth Israel Deaconess Medical Center - Boston
Oregon
- Oregon Health and Sciences University - Portland
Pennsylvania
- University of Pennsylvania - Philadelphia
Texas
- Baylor College of Medicine - Houston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 54 participants |
| Start Date | 2017-08-08 |
| Est. Completion | 2018-03-12 |
What the finished NCT03170063 record still lists
NCT03170063 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 54 participants, a relatively small participant target, below the 5,326-participant average among 297 other Parkinson Disease trials with a reported enrollment target (99% lower).
The record links to 1 condition, with Parkinson Disease appearing as the primary indexed condition, and to 1 intervention - of which Procedure/Surgery: Biofluid samplings is the first listed.
NCT03170063 lists 5 locations in 5 states (Illinois, Massachusetts, Oregon).
Frequently Asked Questions
What is clinical trial NCT03170063 about?
NCT03170063 is a clinical study titled "FoxBioNet Pilot Project: SAVE (Synuclein Assay Validation Effort)". The overall objective of this study is to compare the performance of available oligomeric and phosphorylated a-synuclein assay in cerebrospinal fluid and blood.
What is the current status of trial NCT03170063?
This trial is currently completed. The enrollment target is 54 participants. The study started on 2017-08-08. Estimated completion is 2018-03-12.
What conditions does trial NCT03170063 study?
This clinical trial studies the following conditions: Parkinson Disease.
What interventions are being tested in trial NCT03170063?
The interventions under investigation include: Procedure/Surgery: Biofluid samplings (PROCEDURE).
Who is sponsoring clinical trial NCT03170063?
This trial is sponsored by Michael J. Fox Foundation for Parkinson's Research, which has 14 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03170063 being conducted?
This trial has 5 study locations across Illinois, Massachusetts, Oregon, Pennsylvania, Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Parkinson Disease
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT03170063's enrollment target sits among peer trials
54 151st of 297 higher than 146 of 297 other Parkinson Disease trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Parkinson Disease trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Evaluation of Correlation Between Oculometric Measures and Clinical Assessment in Parkinson's Disease
RECRUITING · NA
-
Colonoscopic Detection of Phosphorylated Alpha-synuclein for Parkinson's Diagnosis
RECRUITING
-
University of Delaware Parkinson's Disease Registry
RECRUITING
-
Neocortical Microarchitecture of Executive Function
RECRUITING · NA
-
Modification of Threat Interpretation Bias to Reduce Anxiety in Neurodegenerative Movement Disorders (Aim 3)
RECRUITING · NA
-
Intranasal Insulin and Glutathione as an Add-On Therapy in Parkinson's Disease
RECRUITING · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01269853 · 54 participants · Phase 1
Repeated Super-selective Intraarterial Cerebral Infusion of Bevacizumab (Avastin) for Treatment of Relapsed GBM and AA
- NCT02390752 · 54 participants · Phase 1
Phase I Trial of TURALIO(R) (Pexidartinib, PLX3397) in Children and Young Adults With Refractory Leukemias and Refractory Solid Tumors Including Neurofibromatosis Type 1 (NF1) Associated Plexiform Neurofibromas (PN) and Tenosynovial Giant Cell Tumor ...
- NCT02991248 · 54 participants · NA
Improve Dynamic Lateral Balance of Humans With SCI
- NCT02993900 · 54 participants · NA
Image-Guided Gynecologic Brachytherapy
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI